How AI Is Transforming Drug Creation – Wall Street Journal (subscription)


Wall Street Journal (subscription)
How AI Is Transforming Drug Creation
Wall Street Journal (subscription)
The big difference between AI-driven drug trials and traditional ones, says Niven Narain, chief executive of Berg, is we're not making any hypotheses up front. We're not allowing [human] hypotheses to generate data. We're using the patient-derived ...

View original post here:

How AI Is Transforming Drug Creation - Wall Street Journal (subscription)

Related Posts

Comments are closed.